About 250mg Gefticip Gefitinib Tablets
| Dose/Strength |
250 mg |
| Manufacturer |
Cipla Ltd |
| Packaging Type |
Box |
| Pack Size |
30 Tablets |
| Brand Name |
Gefticip |
| Composition |
Gefitinib |
| Treatment |
Treatment of Non Small Cell Lung Cancer |
Gefticip Tablet is used in the treatment of non-small cell lung cancer. It is used in patients in which it has spread to other parts of the body, who have abnormal epidermal growth factor receptor (EGFR) genes, and who have not had previous treatment for cancer.
How Gefticip 250mg WorksGefticip 250mg tablets function as a targeted therapy by inhibiting the epidermal growth factor receptor (EGFR), a protein involved in cell growth and division. By blocking EGFR, Gefitinib hinders the proliferation of cancer cells, making it highly effective for patients with EGFR mutation-positive advanced NSCLC.
Proper Administration and Dosage GuidelinesGefticip is designed for oral administration, with each tablet containing 250mg of Gefitinib. It should be taken once daily or as specifically instructed by your oncologist. Adhering to the prescribed schedule maximizes therapeutic benefit while reducing the risk of side effects.
Storage and PackagingEach bottle or blister pack contains 30 tablets, formulated for optimal stability. Store the medication below 30C, shielded from direct light and moisture, to maintain efficacy throughout its 24-month shelf life. Always keep the product out of reach of children.
FAQ's of 250mg Gefticip Gefitinib Tablets:
Q: How should Gefticip 250mg Gefitinib Tablets be taken?
A: Gefticip 250mg tablets are intended for oral use only. Take one tablet daily, or as advised by your oncologist. Swallow the tablet with water and avoid crushing or chewing it. Consistency in administration time each day is encouraged.
Q: What is Gefticip 250mg used for?
A: Gefticip 250mg Gefitinib Tablets are primarily used as first-line therapy for adults with advanced non-small cell lung cancer (NSCLC) that is EGFR mutation-positive. Your oncologist will determine if Gefticip is suitable for your specific cancer type.
Q: When can patients expect to see the benefits of Gefticip?
A: The therapeutic effects of Gefticip may vary depending on individual response and disease progression. It is important to attend follow-up appointments with your oncologist, who will monitor your response through scheduled assessments and adjust your treatment as necessary.
Q: Where is Gefticip 250mg manufactured and is it approved?
A: Gefticip 250mg is manufactured in India by a WHO-GMP certified facility, ensuring compliance with global quality standards for safety and efficacy.
Q: What side effects are associated with Gefticip?
A: Common side effects may include rash, diarrhea, nausea, loss of appetite, and dry skin. Promptly inform your healthcare provider if you experience severe or persistent side effects for further guidance.
Q: Who should not take Gefticip 250mg?
A: Gefticip should not be used by patients with known hypersensitivity to Gefitinib or any of its excipients. Pregnant and breastfeeding women should avoid this medication due to potential risks.
Q: How should Gefticip be stored for best results?
A: Store Gefticip tablets below 30C, in a dry place protected from light and moisture. Ensure the bottle or blister pack is tightly closed and out of reach of children.